Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
41.27
-0.10 (-0.24%)
Jul 27, 2026, 2:15 PM EDT - Market open
Qiagen Revenue
Qiagen had revenue of $492.32M in the quarter ending March 31, 2026, with 1.83% growth. This brings the company's revenue in the last twelve months to $2.10B, up 4.79% year-over-year. In the year 2025, Qiagen had annual revenue of $2.09B with 5.65% growth.
Revenue (ttm)
$2.10B
Revenue Growth
+4.79%
P/S Ratio
4.08
Revenue / Employee
$368,222
Employees
5,700
Market Cap
8.53B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.09B | 111.79M | 5.65% |
| Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
| Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
| Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
| Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
| Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
| Dec 31, 2019 | 1.53B | 24.58M | 1.64% |
| Dec 31, 2018 | 1.50B | 84.31M | 5.95% |
| Dec 31, 2017 | 1.42B | 79.55M | 5.95% |
| Dec 31, 2016 | 1.34B | 57.01M | 4.45% |
| Dec 31, 2015 | 1.28B | -63.79M | -4.74% |
| Dec 31, 2014 | 1.34B | 42.79M | 3.29% |
| Dec 31, 2013 | 1.30B | 47.53M | 3.79% |
| Dec 31, 2012 | 1.25B | 84.71M | 7.24% |
| Dec 31, 2011 | 1.17B | 82.32M | 7.57% |
| Dec 31, 2010 | 1.09B | 77.61M | 7.69% |
| Dec 31, 2009 | 1.01B | 116.85M | 13.09% |
| Dec 31, 2008 | 892.98M | 243.20M | 37.43% |
| Dec 31, 2007 | 649.77M | 184.00M | 39.50% |
| Dec 31, 2006 | 465.78M | 67.38M | 16.91% |
| Dec 31, 2005 | 398.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.27B |
| Charles River Laboratories International | 4.03B |
| Revvity | 2.90B |
| Medpace Holdings | 2.78B |
| RadNet | 2.14B |
| Sotera Health Company | 1.19B |
| Guardant Health | 1.08B |
| Veracyte | 541.74M |
QGEN News
- 11 days ago - QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - Business Wire
- 12 days ago - QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast - Business Wire
- 12 days ago - Qiagen price target raised to $44 from $40 at TD Cowen - TheFly
- 12 days ago - Qiagen expands QIAstat-Dx bloodstream infection testing menu in Europe - TheFly
- 12 days ago - QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe - Business Wire
- 13 days ago - Qiagen downgraded to Hold from Buy at Berenberg - TheFly
- 18 days ago - Qiagen gains after report of early PE interest including EQT, Advent - TheFly
- 18 days ago - Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports - Reuters